Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 0.65
Day High 0.66
Open:0.66
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aleafia Health Inc is a vertically integrated cannabis health and wellness company which owns three cannabis product and cultivation facilities where it produces a diverse portfolio of commercially high-margin derivative products including oils, capsules and sprays. The company operates national network of medical cannabis clinics and has seen over 60,000 patients to date.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Consumer Spending on Cannabis Grows as More Dispensaries Open Their Doors
- PR Newswire - Wed Nov 20, 8:00AM CST
PR Newswire - CMTX
Wed Nov 20, 8:00AM CST
The U.S. cannabis industry has drastically evolved ever since Colorado and Washington decided to legalize recreational cannabis five years ago. The two states were the first in the U.S. to fully legalize adult-use cannabis and since then, a total of 11 states and the District of Columbia have legalized recreational use. However, some regions are much more developed than others in terms of the overall consumer base and revenue delivered. For instance, Colorado reported total revenues of USD 683.52 Million during its first year of legalization in 2014. So far in 2019, from the months of January to September, the state has reported total marijuana sales of USD 1.31 Billion. On the other hand, Massachusetts, which is a much smaller marketplace, reported USD 138.9 Million in the six full months (November 2018 to May 2019) of operations. The staggering revenue margins are a direct result of Colorado's early adoption in comparison to Massachusetts' more recent foray into the industry. To put Colorado's cannabis market into perspective, there were 364 dispensaries in the city of Denver alone in 2018. Among the 364 dispensaries, 169 locations were recreational or "retail marijuana stores," while 195 were medical dispensaries. Overall, the number of dispensaries in Denver was more than triple all of the Starbucks and McDonald's in the city, 111. Meanwhile, Massachusetts had 25 recreational dispensaries in operation as of August 2019, according to the Boston Globe. Generally, the discrepancy between Colorado and Massachusetts hints that the cannabis industry is still within its infancy stage and requires time to mature. And as more people begin to explore the cannabis marketplace, the industry is positioned to experience substantial growth in the shortcoming future. According to data compiled by New Frontier Data, the U.S. legal cannabis market was valued at USD 10.3 Billion in 2018. By 2025, the market is expected to reach USD 30 Billion while exhibiting a CAGR of 14%. Global Payout, Inc. (OTC: GOHE), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF), United Cannabis Corporation (OTC: CNAB), GB Sciences, Inc. (OTC: GBLX)
Regulators Change Tact on CBD Use as Positive Clinical Results Mount
- PR Newswire - Tue Oct 29, 8:00AM CDT
PR Newswire - CMTX
Tue Oct 29, 8:00AM CDT
Canada made headlines in 2018 after it became the second country in the world to completely legalize adult cannabis use. The country's Prime Minister Justin Trudeau was a strong advocate for legalization and ultimately, the country decided to pass new legislation and initiate legal adult-use in late 2018. However, despite Canada's legal market, the enormous U.S. market continues to cast a cloud over its northern neighbor, even though the U.S. has not yet moved to federally legalize cannabis. Instead, the U.S. government has granted states the jurisdiction to legalize cannabis for either medical or recreational purposes. And as of June 2019, 33 states and the District of Columbia allowed the use of cannabis for medical applications. Moreover, 11 of those states, including the District of Columbia have legalized adult recreational use. Overall, the U.S. is the primary global market driver because of its early adoption, dating back to the late 1990s when states such as California, Oregon, Alaska, and Washington were the first to implement a medicinal cannabis program. However, the industry was completely reshaped when Colorado and Washington legalized recreational cannabis in 2014. However, despite Colorado and Washington's efforts, the topic of adult-use legalization is still dubious among world political leaders. Nonetheless, a handful of countries have decided to legalize medical cannabis. Specifically, most countries are using CBD-based products in their medical programs. CBD or cannabidiol is a chemical compound found within the hemp plant, which falls under the cannabis family. Regulators are more inclined to approve CBD because it does not cause any dependency or stimulate psychotropic effects, unlike THC. As a result, CBD is having prominent impact on global markets as regulators move to use it as an alternative to traditionally prescribed medications. According to data compiled by MarketsandMarkets, the global cannabis market was valued at USD 10.3 Billion in 2018. By 2023, the market is expected to reach USD 39.4 Billion while exhibiting a CAGR of 30.7% during the forecast period. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), General Cannabis Corp. (OTC: CANN), The Supreme Cannabis Company, Inc. (OTC: SPRWF) (TSX: FIRE), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX-V: XLY), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF)
Growing Awareness of CBD's Multifaceted Nature Eases Pressure from Regulators
- PR Newswire - Tue Oct 22, 8:00AM CDT
PR Newswire - CMTX
Tue Oct 22, 8:00AM CDT
The growing awareness of cannabidiol or CBD's health benefits has pushed the market into mainstream retail. Researchers have praised CBD for its multi-faceted uses such as its ability to alleviate minor conditions like headaches. However, CBD can also be used to treat serious symptoms associated with medical conditions such as cancer, epilepsy, and multiple sclerosis. Moreover, researchers have mentioned that CBD helps with quitting smoking and also mitigates the withdrawal symptoms. As a result, several countries are considering decriminalizing cannabis and potentially looking into legalizing it for recreational and medicinal purposes. For instance, countries such as Portugal, Canada, Ireland, Jamaica, Australia, Germany, and South Africa have all legalized cannabis for medical applications. Meanwhile, countries such as New Zealand and Mexico are possibly exploring legalizing cannabis entirely. However, the process to legalize cannabis is a tedious and lengthy process. Subsequently, more countries are inclined to legalize just the CBD aspect of the plat. To note, CBD is a derivative of cannabis, but it does not imbue its user with psychoactive effects unlike its THC counterpart. However, after extensive clinical trials, researchers have highlighted that CBD does offer similar therapeutic effects. And now, many see legalizing CBD is yet another step to potentially fully legalizing cannabis. According to data compiled by Technavio, the global CBD market is expected to accelerate at a CAGR of 31% during the forecast period from 2018 to 2022. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), HEXO Corp. (NYSE: HEXO) (TSX: HEXO), MariMed Inc. (OTC: MRMD), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF)
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.62 +6.45% increase
on 11/18/19
Period Open:0.71
Price movement based on the high, low and last over the given period.
1.03 -35.92% decrease
on 11/12/19
-0.05 (-7.04%) decrease
since 11/06/19
3-Month 0.62 +6.45% increase
on 11/18/19
Period Open:1.05
Price movement based on the high, low and last over the given period.
1.06 -37.74% decrease
on 09/09/19
-0.39 (-37.14%) decrease
since 09/06/19
52-Week 0.62 +6.45% increase
on 11/18/19
Period Open:1.42
Price movement based on the high, low and last over the given period.
2.93 -77.47% decrease
on 02/05/19
-0.76 (-53.52%) decrease
since 12/06/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies